Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Neuropharmacol. 2011 Sep;9(3):468-77. doi: 10.2174/157015911796557939.

Toxicities of immunosuppressive treatment of autoimmune neurologic diseases.

Author information

  • 1Neuro-Oncology Program, Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center and Departments of Neurology and Medicine, Dartmouth Medical School, One Medical Center Drive Lebanon NH 03756, USA.

Abstract

In parallel to our better understanding of the role of the immune system in neurologic diseases, there has been an increased availability in therapeutic options for autoimmune neurologic diseases such as multiple sclerosis, myasthenia gravis, polyneuropathies, central nervous system vasculitides and neurosarcoidosis. In many cases, the purported benefits of this class of therapy are anecdotal and not the result of good controlled clinical trials. Nonetheless, their potential efficacy is better known than their adverse event profile. A rationale therapeutic decision by the clinician will depend on a comprehensive understanding of the ratio between efficacy and toxicity. In this review, we outline the most commonly used immune suppressive medications in neurologic disease: cytotoxic chemotherapy, nucleoside analogues, calcineurin inhibitors, monoclonal antibodies and miscellaneous immune suppressants. A discussion of their mechanisms of action and related toxicity is highlighted, with the goal that the reader will be able to recognize the most commonly associated toxicities and identify strategies to prevent and manage problems that are expected to arise with their use.

KEYWORDS:

Immunosuppressive therapy; auto-immune neurologic disease.; toxicity

PMID:
22379461
[PubMed]
PMCID:
PMC3151601
Free PMC Article

Images from this publication.See all images (2)Free text

Fig. (1)
Fig. (2)
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk